With regard to clinical disease activity, neuroimaging, and immune responses, the majority of patients in our cohort were stable. Decreased lymphocyte cell numbers and altered cell ratios returned to normal 14 months after cessation of natalizumab. No infectious complications were observed.
Frank wrote:Hi Harry,
actually I have not been in any trial with Tysabri and I also dont know about any other publications on non stable patients.
I suspended my Tysabri infusions in favour of giving ABX a try for a year. After completing my ABX experience i deceided to go back to Tysabri, so far Tysabri seems to work fine for me.
Users browsing this forum: No registered users